Compare · MAZE vs RVMD
MAZE vs RVMD
Side-by-side comparison of Maze Therapeutics Inc. (MAZE) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MAZE and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $36.09B, about 19.5x MAZE ($1.85B).
- RVMD has been more active in the news (13 items in the past 4 weeks vs 7 for MAZE).
- RVMD has more recent analyst coverage (25 ratings vs 9 for MAZE).
- Company
- Maze Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $1.85B
- $36.09B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 7
- 13
- Recent ratings
- 9
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest MAZE
- SEC Form 10-Q filed by Maze Therapeutics Inc.
- Maze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Chief Executive Officer Coloma Jason V sold $1,043,766 worth of shares (34,501 units at $30.25) as part of a pre-agreed trading plan (SEC Form 4)
- Maze Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 144 filed by Maze Therapeutics Inc.
- CSBO Dandekar Atul sold $240,532 worth of shares (7,500 units at $32.07) as part of a pre-agreed trading plan (SEC Form 4)
- Canaccord Genuity initiated coverage on Maze Therapeutics with a new price target
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Latest RVMD
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits